Markets

Insider Trading

Hedge Funds

Retirement

Opinion

ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) stands against the other cancer stocks.

Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences. As of 2024, 11 of the top 15 diseases globally by the number of active drugs were cancer-related. Breast cancer led the pack with approximately 1,031 active drugs in development. According to WHO, by 2050, over 35 million new cancer cases are projected, marking a 77% increase from the estimated 20 million cases in 2022. This sharp rise in the global cancer burden is driven by an aging and expanding population, along with increased exposure to various risk factors, many of which are linked to socioeconomic development. Additionally, low- and middle-income countries have access to less than half of the cancer medications deemed essential by the World Health Organization (WHO), while the cancer burden in these areas continues to grow. Without action, nearly 75% of global cancer deaths are projected to occur in these regions within the next decade.

Traditionally, cancer drugs were designed to slow cell replication or kill cancer cells more quickly than healthy ones. While effective for certain cancer types, new methods are now emerging, such as modifying immune cells, utilizing mRNA, and enabling early detection through simple blood tests. Advancing the understanding, prevention, screening, and treatment of cancer is critical to reducing its global burden, but it comes at a rising cost, with global oncology spending projected to surpass $250 billion this year.

With this in mind, biotech and pharmaceutical companies are racing to develop cutting-edge therapies for cancers such as lung, breast, and prostate. As no single cure for cancer exists, developing a cancer drug that can treat multiple types of the disease is highly lucrative. For instance, Merck’s Keytruda generated $25 billion in revenue last year alone. Even in its fourth year on the market, back in 2018, the drug brought in $7.2 billion for the company. Moreover, In 2023, German biotechnology company BioNTech SE and the UK government signed a Memorandum of Understanding (MoU) to deliver personalized mRNA-based cancer immunotherapies to up to 10,000 patients by 2030.

These factors are driving ongoing breakthroughs in the oncology market and enhancing its prospects. Back in 2023, over 25 new oncology active substances were introduced globally, along with the initiation of more than 2,000 new clinical trials. These trials span innovative treatments such as cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies. In 2023, the global oncology market was valued at around $201.75 billion and is projected to surpass $518.25 billion by 2032, with a compound annual growth rate (CAGR) of 11.3% from 2024 to 2032 (as per estimates by Fortune Business Insights). This growth is driven by the increasing prevalence of cancer, the introduction of new drugs, product approvals, and expanding research in the field.

Our Methodology

To compile our list of the 10 worst cancer stocks to buy according to short sellers, we focused on cancer-related stocks with substantial short interest (at least 10%). Despite this, these stocks remain favored by hedge funds and market analysts. The list is ranked based on the percentage of outstanding shares that have been sold short, in ascending order.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

A scientist studying a brain penetrant inhibitor as part of precision medicine research.

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Short % of Float: 28.47%

Number of Hedge Fund Holders: 20

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is a biotech firm based in California, dedicated to developing innovative treatments for cancer, particularly those resistant to conventional chemotherapy.

Stifel recently initiated coverage of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) with a Buy rating and a price target of $20.00. The firm emphasized the company’s potential in the prostate cancer treatment market, particularly with its ORIC-944 product, which is slated to enter Phase 3 trials in 2025. ORIC-944, which targets metastatic castration-resistant prostate cancer (mCRPC), employs PRC2 inhibition combined with androgen receptor pathway inhibitors (ARPIs). Stifel noted that PRC2 inhibition could achieve success similar to the ARPI class, which generated approximately $5 billion in sales over the past decade. Additionally, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is developing a second asset, an EGFR TKI, expected to produce valuable data from Phase 1b trials in early 2025.

The company recently bolstered its financial position with a $125 million private placement from healthcare specialist funds in January 2024. As of March 31, 2024, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) reported $331.5 million in cash, cash equivalents, and investments, which it anticipates will support its operations through late 2026.

As of June 30, Andreas Halvorsen’s Viking Global is the largest shareholder in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), with a stake valued at $28.28 million.

Overall ORIC ranks 2nd on our list of the worst cancer stocks to buy according to short sellers. While we acknowledge the potential of ORIC as an investment, with the artificial intelligence revolution just beginning, there are lesser-known AI stocks trading at attractive valuations that could offer even greater promise for portfolio diversification. If you’re seeking an AI stock with even more promise than ORIC and trading at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…